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BACKGROUND: In several settings, a shorter time to di-
agnosis has been shown to lead to improved clinical out-
comes. The implementation of a rapid laboratory testing
allows for a pre-visit testing in the outpatient clinic,mean-
ing that test results are available during the first outpa-
tient visit.
OBJECTIVE: To determine whether the pre-visit labora-
tory testing leads to a shorter time to diagnosis in the
general internal medicine outpatient clinic.
DESIGN:An “on-off” trial, allocating subjects to one of two
treatment arms in consecutive alternating blocks.
PARTICIPANTS:All new referrals to the internalmedicine
outpatient clinic of a university hospital were included,
excluding second opinions. A total of 595 patients were
eligible; one person declined to participate, leaving data
from 594 patients for analysis.
INTERVENTION: In the intervention group, patients had
a standardized pre-visit laboratory testing before the first
visit.
MAIN MEASURES: The primary outcome was the time to
diagnosis. Secondary outcomes were the correctness of
the preliminary diagnosis on the first day, health care
utilization, and patient and physician satisfaction.
KEY RESULTS: There was no difference in time to diag-
nosis between the two groups (median 35 days vs 35 days;
hazard ratio 1.03 [0.87–1.22]; p = .71). The pre-visit test-
ing group had higher proportions of both correct prelim-
inary diagnoses on day 1 (24% vs 14%; p = .003) and
diagnostic workups being completed on day 1 (10% vs
3%;p < .001). The intervention grouphadmore laboratory
tests done (50.0 [interquartile range (IQR) 39.0–69.0] vs
43.0 [IQR 31.0–68.5]; p < .001). Otherwise, there were no
differences between the groups.
CONCLUSIONS: Pre-visit testing did not lead to a shorter
overall time to diagnosis. However, a greater proportion of
patients had a correct diagnosis on the first day. Further
studies should focus on customizing pre-visit laboratory
panels, to improve their efficacy.
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INTRODUCTION
A shorter time to diagnosis has been shown to lead to im-
proved clinical outcomes in some, but not all health care
settings.1–4 Given that the majority of medical decisions rely
on a laboratory testing,5 speeding up access to laboratory
results may lead to earlier diagnoses. For instance, faster
turnaround times of microbiology tests have been shown to
lead to faster initiation of adequate antibiotic therapy and
shorter inpatient length of stay.6,7
One way to speed up the diagnostic process is through a
pre-visit laboratory testing, in which patients have the labora-
tory testing done directly prior to their doctor’s appointment,
and the tests are performed with a short turnaround time at a
routine clinical laboratory. By necessity, the pre-visit testing
makes use of standardized laboratory test panels, as the patient
has not been examined yet so the information from the history
and physical examination is not yet available to guide the
selection of laboratory tests. Standardized laboratory panels
invariably include unnecessary tests, which potentially lead to
downstream overutilization.8
In the Netherlands, the pre-visit testing is not the currently
standard practice in the outpatient clinic, due to the often long
turnaround times in the laboratory.
The information reported in this manuscript has not been previously
presented.
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In 2014, the Central Diagnostic Laboratory of the Univer-
sityMedical Centre Utrecht (UMCUtrecht) introduced a rapid
testing for a broad panel of routine laboratory tests for clinical
chemistry, hematology, coagulation, and endocrinology. This
service guarantees that the results of these tests are available
within 60 min after the sample arrives at the laboratory. This
rapid testing enables the implementation of the pre-visit testing
in the outpatient clinic, making the test results available to the
treating physician at the time of the visit, as opposed to usual
care, in which the treating physician orders laboratory tests
during the visit and the test results are only available after-
wards, so the patient has to return for another visit.
Consequently, this “on-off” trial was set up to evaluate
whether the pre-visit laboratory testing benefits the patient
and physician alike, shortening the time to diagnosis in newly
referred outpatients, and to evaluate the downstream conse-
quences of potential overutilization.
METHODS
Trial Design
This is a single-center controlled “on-off” trial, in which
patients were alternately allocated to the intervention group
or the usual care group in 3-month blocks.9 Subjects were not
randomized individually, because it was not feasible to incor-
porate the two different testing strategies in the laboratory
order management system simultaneously.
In the intervention group, patients had laboratory tests per-
formed directly prior to their first visit to the outpatient clinic,
and in the usual care group, laboratory tests were done
afterwards.
Patient Selection
All adult patients newly referred to the general internal med-
icine outpatient clinic of the University Medical Center
Utrecht (UMC Utrecht), a large university hospital in Utrecht,
the Netherlands, were eligible for inclusion. Referrals for
second opinions were excluded because these patients often
already have a diagnosis.
In the Netherlands, patients require a referral from their
primary care physician before they visit an outpatient clinic.
This referral consists of a letter with the reason of referral,
sometimes accompanied by laboratory results, but not with the
entire patient record due to privacy regulations. The general
internal medicine outpatient clinic of the UMC Utrecht
receives the primary care physicians’ referrals electronically
(and by regular mail). New referrals are triaged by an attending
physician and are then randomly assigned to either a resident
or an attending physician for an outpatient consultation. The
residents are required to confer all consultations with their
supervising attendings.
Based on an estimated sample size of 460 participants, four
3-month blocks were initially planned from April 2015 to
April 2017. However, because inclusion went slower than
previously anticipated, the inclusion period was extended to
August 2017 by adding two 2-month blocks.
Intervention
In the intervention group, patients were asked to have their blood
drawn 1 h before their scheduled appointment for their first visit,
so that the treating physician had access to the test results during
the visit. All patients in the intervention group received the same
standard laboratory panel, regardless of the referral reason. This
panel had been established before the start of the trial by a panel
of experienced internists and clinical chemists and comprised the
following tests: hemoglobin, cell counts/differential, sodium,
potassium, calcium, urea, creatinine, alkaline phosphatase,
gamma-glutamyl transferase (GGT), glucose, aspartate transam-
inase (AST), alanine transaminase (ALT), lactate dehydrogenase
(LDH), albumin, C-reactive protein (CRP), thyroid-stimulating
hormone (TSH), erythrocyte sedimentation rate (ESR), and a
urine strip screening.
In the usual care group, laboratory tests were ordered at the
discretion of the treating physician during the first visit and test
results were only available afterwards.
In both groups, all other aspects of medical care, such as
imaging tests and the planning of follow-up visits, were at the
discretion of the treating physician.
Outcomes and Measures
Baseline Characteristics. For all patients, age at referral and
gender were retrieved from the Utrecht Patient Oriented
Database (UPOD), an infrastructure of relational databases
comprising data on patient characteristics, hospital discharge
diagnoses, medical procedures, medication orders, and
laboratory tests for all patients treated at UMC Utrecht.
UPOD data acquisition and management is in accordance
with current regulations concerning privacy and ethics. The
structure and content of UPOD have been described in more
detail elsewhere.10 Furthermore, whether the physician
performing the first consultation was a resident or an
attending was obtained from the patient charts. Referral
reasons and, if available, the results of the laboratory testing
performed by the referring physician were taken from the
referral letter. Referral reasons were grouped into the
following categories: anemia, fatigue, weight loss, gastro-
intestinal complaints, abnormal laboratory test result(s) (other
than anemia), lymphadenopathy/suspected malignancy, and
other. These categories were non-exclusive as some patients
had more than one referral reason.
Primary Outcome. The primary outcome was the time to
diagnosis, defined as the number of days between the first
visit to the outpatient clinic and the final diagnosis being
made. The date of final diagnosis was defined as the date the
patient was informed of the diagnosis and after which no
further tests or examinations were performed to confirm or
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refute this diagnosis. If a patient had more than one diagnosis,
the date of the last diagnosis was used.
An expert panel of internal medicine physicians assessed
the date of the final diagnosis. Assessment was planned 2
years after the patient’s initial visit. Each case was individually
assessed by two panelists, and a third panelist was consulted
when there was a disagreement. If two out of three panelists
agreed on a date, this date was chosen. Cases where none of
the panelists agreed on a date were resolved by consensus
through discussion between the panelists. Inter-rater agree-
ment was evaluated using the one-way random effects intra-
class coefficient.11
Secondary Outcomes. Secondary outcomes were the
correctness of the preliminary diagnosis at the first visit to
the outpatient clinic, utilization of health care resources during
the diagnostic process, and patient and physician satisfaction.
Correctness of the Preliminary Diagnosis
The correctness of the preliminary diagnosis on the first day
was assessed using two parameters: firstly, the proportion of
patients in whom the treating physician’s preliminary diagno-
sis at the first visit agreed with the final diagnosis, and sec-
ondly, the proportion of patients in whom the diagnostic
process was completed on the first day.
Utilization of Health Care Resources
Health care utilization was measured by the number of med-
ical procedures during the diagnostic process, including the
pre-visit laboratory tests. Specifically, the number of outpa-
tient clinic visits, clinical admissions, laboratory tests, veni-
punctures, imaging, and endoscopies were collected from the
UPOD database. Furthermore, the physicians were asked to
report the duration of the first consultation at the outpatient
clinic, in minutes.
Patient and Physician Satisfaction
Patient satisfaction was assessed through a questionnaire,
which was handed out to patients at their first visit to the
outpatient clinic. Patients were asked about their preferences
regarding laboratory testing strategies, as well as their satis-
faction with their first visit to the outpatient clinic by an overall
grade (1–10) and by using a modified Patient Satisfaction
Questionnaire Short-Form (PSQ-18)12 that excluded questions
on financial consequences and accessibility of health care, as
these items were not thought to be relevant in this setting.
Physicians were asked three yes-or-no questions regarding
satisfaction with testing strategies after the first visit: whether
they had a good overview of the patient’s problem, whether
they were able to help the patient efficiently, and whether the
diagnosis was already in sight.
Statistical Analyses
A sample of 200 patients per treatment arm was required to
detect a 7-day difference in the mean time to final diagnosis
with a power of 80% and an alpha of .05, assuming a standard
deviation of 25 days. To compensate for the non-normality of
the data, the required sample size was increased by 15%,
yielding a required total sample size of 230 patients in each
group.13 All analyses were done according to the intention-to-
treat principle.
Survival analysis was used to evaluate the primary outcome
(time to diagnosis) to account for censoring due to loss to
follow-up. A hazard ratio was calculated using Cox propor-
tional hazards analysis. A Kaplan-Meier plot as well as
medians and interquartile ranges for the time to diagnosis
was also reported to aid with interpretation of the data.
Subgroup analyses of the primary outcome were performed
on gender, referral reason, whether the referral letter contained
the results of the laboratory testing by the referring physician,
and whether the physician who treated the patient at the first
visit to the outpatient clinic was a resident or attending
physician.
The rates of correct preliminary diagnoses on the first day
and diagnostic processes being completed on the first day
were tested with Pearson’s χ2 test. The number of medical
procedures in the diagnostic process was tested using negative
binomial regression. Patient preferences were tested using the
Wilcoxon-Mann-Whitney test and patient satisfaction was
tested using Student’s t test. Physician preferences were tested
using Pearson’s χ2 test. The duration of the first visit was
tested using Student’s t test.
All statistical analyses were performed in R version 3.5.1.14
Ethical Considerations
Because both laboratory testing strategies we investigated
were already used in clinical practice and no other burden
was imposed on patients other than the questionnaire, the
institutional review board waived the requirement for in-
formed consent. Patients had the opportunity to opt out of




In total, 595 patients were eligible for inclusion. One patient in
the usual care group declined to participate, which left 594
patients for inclusion: 256 in the intervention group and 338 in
the usual care group. Thirty-four patients (13%) in the inter-
vention group erroneously did not have pre-visit laboratory
testing done. All 594 patients were included in the analyses. A
flowchart of the inclusions is provided in Figure 1. Baseline
characteristics are presented in Table 1. The mean time be-
tween the initial visit and the expert panel’s assessment was
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713 days (95% CI 701–726 days). Loss to follow-up was 6%
after a median follow-up time of 138 days (43–270).
Time to Diagnosis
There was no difference in time to diagnosis (in days) between
the two groups (Fig. 2; hazard ratio 1.03 [0.87–1.22]; p = .71).
A definitive diagnosis was made in 94% of patients. For these
patients, median time to diagnosis was 35.0 days (interquartile
range 14.0–77.3) in the intervention group and 35.0 days (IQR
14.0–83.0) in the control group. A list of the final diagnoses is
provided in Supplementary Table 1.
When establishing the time to diagnosis, the two experts
agreed in 408 cases (69%). When a third reviewer was neces-
sary to resolve discrepancies, there was an agreement between
two of the three experts in 551 cases (77%); the remaining 43
cases (23%) were resolved through a discussion. The one-way
random effects intra-class coefficient was 0.63, indicating a
moderate inter-rater agreement.
There were no differences in time to diagnosis between the
intervention and control groups for subgroups based on gen-
der, referral reason, the availability of the results of the pre-
referral laboratory testing by the referring physician, or wheth-
er the initial consultation was done by a resident or an attend-
ing physician (Supplementary Table 2).
Diagnosis After First Visit
The rate of agreement between the treating physician’s pre-
liminary diagnosis on the first day and the definitive diagnosis
at the end of the diagnostic process was 24% in the interven-
tion group versus 14% in the control group (p = .003). The
proportion of patients in whom the diagnostic process was
completed on the first day was also significantly higher in the
intervention group (10% vs 3%; p < .001).
Health Care Utilization
Patients in the intervention group had more laboratory tests
done, both on the day of the first visit (median 22.0 [21.0–
26.0] vs 20.0 [10.0–26.0]; p < .001) and during the entire
diagnostic process (median 50.0 [39.0–69.0] vs 43.0 [31.0–
68.5]; p = .001). There were no other differences in the number
of medical procedures during the time to diagnosis. Notably,
the total number of visits to the outpatient clinic was similar in
both groups (2.0 [1.8–4.0] vs 2.0 [2.0–4.0]; p = .63). The first
visit did last slightly longer in the intervention group (48.3
[46.6–49.9] vs 45.0 [42.3–46.7] min; p = .006). All data on
health care utilization are presented in Table 2.
595 newly referred paents
256 in intervenon group 339 in usual care group
0 declined to parcipate
256 included in analysis 338 included in analysis
1 declined to parcipate
222 had pre-visit lab tests   
34 did not have pre-visit lab 
tests done
240 had final diagnosis
16 lost to follow up
319 had final diagnosis
19 lost to follow up
Figure 1 Inclusion flowchart.





Female gender 145 (57%) 207 (62%)
Age 53.9 (51.7–56.1) 51.7 (49.8–53.7)
Referral reason (grouped)*
Abnormal lab test 55 (21%) 45 (13%)
Anemia 28 (11%) 43 (13%)
Fatigue 64 (25%) 83 (25%)
Gastro-intestinal complaints 24 (9%) 41 (12%)
Lymphadenopathy/suspected
malignancy
15 (6%) 17 (5%)
Weight loss 26 (10%) 42 (12%)
Other 65 (25%) 88 (26%)
Availability of pre-referral
laboratory test results
121 (47%) 174 (51%)
Seen by attending physician 27 (11%) 50 (15%)
*Categories are non-exclusive
Vrijsen et al.: Pre-visit Testing and Time to Diagnosis JGIM
Additionally, a post hoc analysis to assess the adequacy of
the standard laboratory panel showed that in 66% of subjects
in the intervention group, additional laboratory tests were
ordered on the first day (Supplementary Table 3).
Satisfaction
There was no difference in physician and patient satisfaction
between the two groups (Tables 3 and 4). However, there were
some differences in patients’ preferences (Supplementary
Figure 1): patients who had had pre-visit laboratory tests done
were more likely to want to learn the diagnosis on the
same day (93% vs 91%; p < .001), and less likely to
want to see the doctor before having laboratory tests done
(17% vs 43%; p < .001). However, they were more likely to
object to more laboratory tests being done than necessary
(16% vs 8%; p = .01).
DISCUSSION
In our single-center on-off study, performing a standardized
laboratory test panel prior to the first visit to the outpatient
clinic did not result in a shorter overall time to diagnosis.
However, it did increase the chance of obtaining a final diag-
nosis during the first visit. The number needed to test in order
to finish the diagnostic process on the first day was 15. In our
questionnaire, the vast majority of patients preferred receiving
Figure 2 The Kaplan-Meier plot of time to diagnosis in days. Hazard ratio 1.03 (0.87–1.22); p = .71.
Table 2 Health Care Utilization During the Diagnostic Process
Pre-visit testing (n = 256) Usual care (n = 338)
Medians + interquartile ranges Medians + interquartile ranges
Visits to out-patient clinic
- Any 2.0 (1.8–4.0) 2.0 (2.0–4.0) p = .63*
- Internal medicine 2.0 (1.0–3.0) 2.0 (1.0–3.0) p = .96*
Teleconsultations 1.0 (0.0–3.0) 1.0 (0.0–2.0) p = .70*
Number of clinical admissions 0.0 (0.0–1.0) 0.0 (0.0–1.0) p = .37*
Clinical admission days 0.0 (0.0–1.0) 0.0 (0.0–1.0) p = .42*
Laboratory tests (total) 50.0 (39.0–69.0) 43.0 (31.0–68.5) p = .001*
Laboratory tests (first day) 22.0 (21.0–26.0) 20.0 (10.0–26.0) p < .001*
Laboratory test orders 3.5 (2.0–5.3) 3.0 (2.0–5.0) p = .11*
Imaging tests 1.0 (0.0–3.0) 1.0 (0.0–2.0) p = .46*
Number of patients with imaging tests n (%) n (%)
Any imaging 180 (70%) 222 (66%) p = .27†
MRI 20 (8%) 21 (6%) p = .55†
CT 62 (24%) 68 (20%) p = .27†
Ultrasound 84 (33%) 108 (33%) p = .89†
Nuclear 19 (7%) 18 (5%) p = .38†
X-ray 111 (43%) 144 (43%) p = .92†
Endoscopy 34 (13%) 57 (17%) p = .28†
MRI, magnetic resonance imaging; CT, computed tomography
*Negative binomial regression
†Pearson’s χ2 test
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their diagnosis on the first day, and at the same time did not
object to having more laboratory tests done than necessary.
Ordering standardized laboratory panels is in sharp contrast
with advice from several guidelines, including Choosing
Wisely recommendations, because of potential overutiliza-
tion.15 Overutilization leads to increased costs, as well as
potentially more false positive test results.16
In this study, patients in the intervention group on average
had 7 more laboratory tests performed during the diagnostic
process. No other differences in health care utilization were
found, which implies that the excess laboratory tests did not
lead to significant downstream overutilization.
To the best of our knowledge, this is the first time that the
effect of the pre-visit laboratory testing on the diagnostic
process in the outpatient setting has been studied.
Several possible explanations for the study’s negative
result can be proposed. First of all, laboratory testing
may not be as important for establishing a diagnosis as
previously hypothesized. This might be especially true
in the setting of a tertiary hospital, which typically has a
more complex case mix that requires a more extensive
diagnostic workup. This might also explain why the pre-
visit testing would have an effect on the number of
correct diagnoses on the first day, as in these cases
typically no additional diagnostic tests were performed.
It might also be argued that the laboratory testing al-
ready performed by the referring physician negated the
effect of the pre-visit testing, although in that case one
would have expected to see an effect in the subgroup
without pre-referral testing.
Alternatively, given that additional tests were ordered after the
first visit in 66% of cases in the pre-visit arm, it might also be
argued that the pre-visit panel proved inadequate in those patients
and that a different ormore extensive test panel would havemade
a difference. However, extending the pre-visit panel would lead
to greater costs and possibly more downstream overutilization.
Tailoring the pre-visit panel to individual patients based on their
referral reason might be a more promising alternative.
One of the strengths of this study is that all subjects were
comprehensively analyzed through a chart review by an expert
panel. As a result, loss to follow-up was limited at 6%.
Furthermore, the study population was relatively unselected,
as all newly referred patients were included, which increases
the study’s external validity.
This study has several limitations. Firstly, the on-off trial design
may have compromised the comparability of the two groups.
Secondly, this was an open-label study. The subjects and
their treating physicians were aware of their allocation. The
expert panelists who determined the time to diagnosis were not
actively informed about the allocation of the subjects they
evaluated, but in many cases, it could be inferred from the
treating physician’s chart notes they reviewed.
Thirdly, the response rate of the patient survey was quite
low at 49% of patients in the intervention group and 39% in
the control group, which could limit the generalizability of the
questionnaire’s results.
Fourthly, the physician survey comprised only three questions,
because we presumed that physicians would not be willing to fill
out longer surveys. This may limit the survey’s applicability.
Finally, even though we found no differences in health care
utilization apart for a modest increase in the number of labo-
ratory tests in the intervention group, not all potentially neg-
ative effects of test overutilization, such as anxiety due to false
positive test results, were monitored for in this study.
In conclusion, the standardized pre-visit laboratory
testing did not lead to a shorter time to diagnosis but
increased the chance of obtaining the correct diagnosis
during the first visit. Further studies should focus on
Table 4 Patient Satisfaction
Respondents, n (%) Pre-visit testing (n = 125 [49%])
(means + 95% confidence interval)
Usual care (n = 131 [39%])
(means + 95% confidence interval)
Overall grade 8.0 (7.8–8.2) 8.1 (7.9–8.3) p = .54
Modified PSQ-18 questionnaire
General satisfaction 3.85 (3.71–3.98) 3.81 (3.66–3.96) p = .72
Technical quality 3.86 (3.75–3.97) 3.73 (3.62–3.84) p = .11
Interpersonal manner 4.35 (4.02–4.26) 4.20 (4.07–4.33) p = .07
Communication 4.14 (4.02–4.26) 4.00 (3.87–4.12) p = .10
Time spent with doctor 4.02 (3.90–4.15) 3.84 (3.70–3.98) p = .05
Differences between the groups were tested using Student’s t test. Items of the PSQ-18 are scored on a 1–5 scale, with high scores reflecting greater
satisfaction with medical care
Table 3 Physician Satisfaction
Pre-visit testing (n = 191)
(% of respondents answering
affirmatively)
Usual care (n = 161)
(% of respondents answering
affirmatively)
Good overview of the problem? 98% 98% p > .99
Able to help the patient efficiently? 65% 71% p = .28
Diagnosis already in sight? 57% 50% p = .24
Differences between the groups were tested using Pearson’s χ2 test
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adaptations and differentiations to the standard pre-visit
laboratory panel.
Supplementary Information The online version contains supple-
mentary material available at https://doi.org/10.1007/s11606-020-
06453-2.
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